Back to results
US 2020/0206301 A1Published application
JNK Inhibitor Molecules For Treatment Of Various Diseases
AssigneeXigen Inflammation Ltd.
InventorsJean-Marc COMBETTE, Catherine DELOCHE
Life of this patent
Estimating the term…
Abstract
The present invention relates to the use of novel JNK inhibitor molecules and their use in a method of treatment of the human or animal body by therapy.
Claims22
A method of treatment of the human or animal body comprising administering to a subject a JNK inhibitor, selected from the group consisting of:
- a) a JNK inhibitor, which comprises an inhibitory (poly-)peptide sequence according to the following general formula:
- (SEQ ID NO:
- 1)
- X1—X2—X3—R—X4—X5—X6—L—X7—L—X8,
- wherein X1 is an amino acid selected from amino acids R, P, Q and r,
- wherein X2 is an amino acid selected from amino acids R, P, G and r,
- wherein X3 is an amino acid selected from amino acids K, R, k and r,
- wherein X4 is an amino acid selected from amino acids P and K,
- wherein X5 is an amino acid selected from amino acids T, a, s, q, k or is absent,
- wherein X6 is an amino acid selected from amino acids T, D and A,
- wherein X7 is an amino acid selected from amino acids N, n, r and K;
- and
- wherein X8 is an amino acid selected from F, f and w, and
- wherein an amino acid residue given in capital letters indicates an L-amino acid, while an amino acid residue given in small letters indicates a D amino acid residue,
- with the proviso that at least one of the amino acids selected from the group consisting of X1, X2, X3, X5, X7 and X8 is/are a D-amino acid(s), and
- b) a JNK inhibitor which comprises an inhibitory (poly-)peptide sequence sharing at least at least 80% sequence identity with SEQ ID NO:
- 1 as defined in a), with the proviso that with respect to SEQ ID NO:
- 1 such inhibitory (poly-)peptide sequence sharing sequence identity with SEQ ID NO:
- 1 maintains the L-arginine (R) residue of SEQ ID NO:
- 1 at position 4 and the two L-leucine (L) residues of SEQ ID NO:
- 1 at positions 8 and 10 and that at least one of the remaining amino acids in said sequence sharing at least at least 80% sequence identity with SEQ ID NO:
- 1 is a D-amino acid.
19 more elements
(canceled)
-16. (canceled)
-29. (canceled)
-64. (canceled)
Dependencies are inferred from the claim text.